



GLOBAL TASK FORCE ON
CHOLERA CONTROL

OCV WG ACTIVITIES FOR 2023

OCV WG meeting
12 October 2022

| Thematic area | Proposed activities for 2023 |
|---------------------|---|
| Guidance | <ul style="list-style-type: none"> • Selection of identified hotspots for OCV use (part of MYP) • Strengthen the GTFCC process for reviewing preventive OCV requests • Support Gavi with completion of market shaping roadmap • Guidelines for allocation of OCV for preventive campaigns among countries • Support ICG secretariat with revision of ICG guidelines on reactive use of OCV • <i>Papers summarizing evidence of protection from single dose use, co-administration</i> |
| Operations | <ul style="list-style-type: none"> • Prepare training materials and conduct training of MoH and consultants for OCV • Develop online version of request/campaign training • Develop tools and relevant guidance documents to ensure standardized M&E of campaigns (continued – OCRA pilots, NEW – review campaign evaluation and integration tools, other?) • Develop webinar to build awareness of new OCV request process through Gavi <i>Include documents on website</i> • OCV strategy (NEW) • <i>Demand documentation (Gavi – expression of interest)</i> |
| Data sharing | <ul style="list-style-type: none"> • Develop dashboard for OCV requests, shipments, and campaigns • Review of OCV use 2013-2021 • Impact of covid on OCV campaigns |

OCV WG RESEARCH PRIORITIES FOR 2023

| Rank | Research Question |
|------|--|
| 1 | What are the optimal OCV schedules (number of doses and dosing intervals) to enhance immune response and clinical effectiveness in children 1 to 5 years of age? |
| 2 | What are potential delivery strategies to optimize OCV coverage in hard-to-reach populations (including during humanitarian emergencies and areas of insecurity)? |
| 3 | Is there additional benefit of adding WASH packages, for example household WASH kits, to an OCV campaign? |
| 4 | What is the optimal number of doses of OCV to be used for follow-up campaigns in communities previously vaccinated with a two-dose schedule? |
| 5 | Can the impact of OCV on disease transmission, morbidity and mortality be maximized by targeting specific populations and/or targeted delivery strategies? |

Discovery of new vaccines

Potential new areas to address

- Evidence to demonstrate safe use of OCV among pregnant women
 - Do we need new research vs use current evidence from Shanchol?
- Duration of protection of OCV
 - Lessons learned from Haiti (case study?)
- Documenting impact of CTC on program
- Vaccine effectiveness post Shanchol?

Strengthen feedback and updates from research partners to the OCV WG

Thank you



GLOBAL TASK FORCE ON
CHOLERA CONTROL

